INDICATION: LONSURF® (trifluridine and tipiracil) tablets are a prescription medicine used to treat people with colon or rectal cancer that has spread to other parts of the body and who have previously been treated with or cannot receive certain chemotherapy medicines. It is not known if LONSURF is safe and effective in children.
INDICATION: LONSURF® (trifluridine and tipiracil) tablets are a prescription medicine used to treat people with colon or rectal cancer that has spread to other parts of the body and who have previously been treated with or cannot receive certain chemotherapy medicines. It is not known if LONSURF is safe and effective in children.

Privacy Policy

INTRODUCTION

Thank you for visiting the Taiho Oncology, Inc. website. Taiho Oncology, Inc. and its parent company, subsidiaries, and affiliates (collectively, “Taiho”) operate a variety of websites designed to provide you with information and services, including but not limited to health resources, corporate news, patient assistance programs, and product information. Some of Taiho's websites also enable healthcare professionals to receive product information and samples. Whether you are a patient, healthcare provider, investor, customer, or job applicant, respect for the privacy of your personal information is very important to us. This statement describes how we collect, use, protect, and disclose the personal information that you share with us when you visit any of our websites. Taiho websites that display this statement are committed to collecting, maintaining, and securing your personal information in accordance with the terms of this Statement. We encourage you to read this Privacy Statement in its entirety before submitting any information. By using this website, and submitting or requesting information, you acknowledge that you understand, and agree with, the provisions of this Privacy Statement.

WHAT INFORMATION DO WE GATHER?

Taiho will not collect personally identifiable information about you unless you provide it voluntarily. You can use many of our websites without telling us who you are or providing us with any personal information. Depending on which website you visit, you may not be able to receive certain information unless you agree to provide us with personally identifiable information. For example, we may collect information from physicians and other healthcare providers who register on our websites in order to verify their licensure status and identity. The type of information collected from you will be based on the specific program that you register for, as indicated at the time of your registration. The information that we may ask you to provide may include your first and last name, your mailing address, your age, birth date, email address, and information about your medical conditions. Taiho limits the collection and processing of personal information to what is necessary to fulfill the purposes for which it is to be used. Taiho will request your consent to collect your personally identifiable information when you register for a program or service. We will also offer you the option to opt out of receiving further communications from Taiho (“opting out” or “unsubscribing”) if you later decide that you no longer want to participate in that program or receive additional information from us.

USE OF COOKIES AND OTHER TAGS

Where permitted by law, non-personally identifiable information and data may be automatically collected through the standard operation of Taiho's Internet service or through the use of “cookies” or “Internet tags” and other similar techniques. This type of anonymous information allows Taiho to evaluate customer interest in its websites and perform other market research activities. Cookies are small text files a website can use to recognize repeated usage, facilitate the user's access to and use of the site, and allow a site to track usage behavior and compile aggregate data that will allow content improvement and targeted advertising. Cookies are programs that come into a user's system but do not damage files. Generally, cookies work by assigning a unique number to the user that has no meaning outside the assigning site. If a user does not want information to be collected through the use of cookies, there is a simple procedure in most browsers that allows the user to deny or accept the cookie feature; however, users should note that cookies may be necessary to provide the user with certain features (e.g., customized delivery of information) available on Taiho's websites.

Taiho also may collect and store the name of the domain and host from which you access the Internet, the Internet protocol (IP) address of the computer you are using, the browser software you use and your operating system, the date and time you access our website, and the Internet address of the website from which you linked directly to our website. We may provide opportunities to contact us to ask questions or provide comments, ideas, and/or suggestions. When you communicate with us and request a response, we may ask you for additional information such as your name, email address, and contact information. If we collect this type of information, we will notify you as to why we are asking for it and how this information will be used. It is completely up to you whether or not you want to provide it.

DATA INTEGRITY AND SECURITY

Taiho takes reasonable steps to ensure that personal data collected are reliable for their intended use, accurate, complete, and current. We use appropriate technical, administrative, and physical safeguards to protect data that pertain to you from loss, misuse, or alteration. In addition, we take steps to ensure that our safeguards take into account new known threats. However, no organization can guarantee the absolute security of personal information. You should keep in mind that Internet transmissions, particularly email transmissions, are never 100% secure or error-free. Accordingly, we caution you to guard your own computer and password against unauthorized access by others.

SHARING YOUR INFORMATION WITH THIRD PARTIES

Taiho will not share your personal information with third parties for their own separate use unless we have obtained your opt‑in consent to do so. When you provide personally identifiable information to Taiho, it will be accessible to some of Taiho's business partners, such as companies we retain to fulfill requests for information, answer telephone calls, or provide assistance to us on specific programs or projects. In addition, Taiho may enter into business relationships with other companies. In those cases, the other companies may also have access to your personally identifiable information. Taiho requires third parties to whom it discloses personal data to protect personal information using substantially similar standards to those required by Taiho. We also require that they do not use your personal information for any separate use that is not specifically authorized by Taiho.

There may also be instances where Taiho may be required to share your information with third parties who have not been retained by Taiho, such as with health authorities to report possible adverse drug experiences, during inspections or audits, or as ordered or directed by courts or other governmental agencies. Many entities receiving personally identifiable information under these conditions have privacy requirements that apply to their handling of your information.

SHARING YOUR INFORMATION WITHIN THE TAIHO GROUP OF COMPANIES

The information that you provide to Taiho may sometimes be shared with other departments within Taiho, as well as Taiho subsidiaries and affiliates within the Taiho global group. This may mean that your personally identifiable information may be transferred outside the U.S. to Taiho affiliates or companies in other countries. Other departments within the Taiho group, and other Taiho companies that may receive your information, will abide by substantially similar privacy requirements relating to your personally identifiable information.

CORRECTING AND ACCESSING YOUR INFORMATION

We encourage you to update the information you provide to us, such as providing us with a new mailing or email address, a name change, or a change in the medical conditions that you have notified us about. This will help us continue to provide information to you that best meets your needs.

Taiho complies with laws and regulations applicable to the right to amend your data in our files. These rights are limited in some ways. In addition, to protect your data from unauthorized access or alteration by third parties, all requests to update or access your information will be subject to verification of your identity.

CHILDREN'S ONLINE PRIVACY

Taiho's websites are not directed at children. The services offered on our websites are designed for individuals who are 18 years of age or older. If your child has submitted personal information and you would like to request that such information be removed, please contact privacyofficer@taihooncology.com.

For more information about protecting the privacy of children online in the United States under the Children's Online Privacy Protection Act, please see http://www.ftc.gov/ogc/coppa1.htm (last accessed January 2013).

LINKS AND THIRD‑PARTY WEBSITES

Many of Taiho's websites contain links or references to third‑party websites as a convenience to you. This Privacy Statement does not cover the practices of those websites. Accessing those sources requires that you leave Taiho's websites. Taiho does not control the content of these third‑party websites and is not responsible for the privacy practices of those websites. Please review the privacy policies on each website that you visit.

UPDATES TO PRIVACY STATEMENT

The foregoing terms are effective as of March, 2014. Taiho may update this Privacy Statement from time to time based on, among other things, changes in applicable laws, development of new websites, and advances in technology. Taiho reserves the right to modify, add, or remove portions of this Privacy Statement at any time at our sole discretion. If we decide to revise this Statement, we will post the revised Statement at this site. We encourage you to review the Statement each time you visit our site.

This Privacy Statement is not intended to and does not create any contractual or other legal rights in or on behalf of any party.

HOW TO CONTACT US

If you have any questions about our Privacy Statement, its implementation, the accuracy of your personal information, or the use of the information collected, please contact us at privacyofficer@taihooncology.com.

You can also mail us at:
Privacy Officer
Taiho Oncology, Inc.
202 Carnegie Drive, Suite 100
Princeton, New Jersey 08540

Important Safety Information +

LONSURF may cause serious side effects, including:

  • Low blood counts. Low blood counts are common with LONSURF and can sometimes be severe and life‑threatening. LONSURF can cause a decrease in your white blood cells, red blood cells, and platelets. Low white blood cells can make you more likely to get serious infections that could lead to death. Your healthcare provider should do blood tests before you receive LONSURF, at day 15 during treatment with LONSURF, and as needed to check your blood cell counts. Your healthcare provider may lower your dose of LONSURF or stop LONSURF if you have low white blood cell or platelet counts

Tell your healthcare provider right away if you get any of the following signs and symptoms of infection during treatment with LONSURF: fever, chills, or body aches.

Before taking LONSURF, tell your healthcare provider about all of your medical conditions, including if you:

  • Have kidney or liver problems
  • Are pregnant or plan to become pregnant. LONSURF can harm your unborn baby
    • Females who can become pregnant should use effective birth control during treatment with LONSURF. Tell your healthcare provider immediately if you become pregnant
    • Males, while on treatment and for 3 months after your last dose of LONSURF, you should use a condom during sex with female partners who are able to become pregnant. Tell your healthcare provider right away if your partner becomes pregnant while you are taking LONSURF
  • Are breast‑feeding or plan to breast‑feed. It is not known if LONSURF passes into your breast milk. Do not breast‑feed during treatment with LONSURF and for 1 day after your last dose of LONSURF

Tell your healthcare provider about all the prescription and over‑the‑counter medicines, vitamins, and herbal supplements you take.

The most common side effects with LONSURF include tiredness, nausea, decreased appetite, diarrhea, vomiting, abdominal pain, and fever.

Tell your doctor if you have nausea, vomiting, or diarrhea that is severe or that does not go away.

These are not all of the possible side effects of LONSURF. For more information, ask your healthcare provider. Call your doctor for medical advice about side effects.